Company intelligence / Profile preview

Chartwell Tetra

Congers, New York, United States

Ownership: Private
Development stage: Other

Overview

Chartwell Tetra is a pharmaceutical company and a subsidiary of Chartwell Pharmaceuticals LLC, specializing in the production of generic prescription medications. The company is the official applicant and manufacturer for generic Tetracycline Hydrochloride, a broad-spectrum antibiotic used for various bacterial infections. Operating out of the United States, Chartwell Tetra leverages the manufacturing and regulatory expertise of its parent organization, which provides contract development and manufacturing services (CDMO) and maintains a portfolio of generic products. The company is part of the Pillar Capital portfolio following its acquisition in 2020.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Chartwell Tetra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chartwell Tetra.

Explore the full profile